Last reviewed · How we verify
Eribulin Injection [Halaven]
Eribulin Injection [Halaven] is a Small molecule drug developed by Institut fuer Frauengesundheit. It is currently FDA-approved. Also known as: Eribulin.
Eribulin Injection, also known as Halaven, is a small molecule medication. It is a synthetic analog of halichondrin B, a compound found in the marine sponge Halichondria okadai.
At a glance
| Generic name | Eribulin Injection [Halaven] |
|---|---|
| Also known as | Eribulin |
| Sponsor | Institut fuer Frauengesundheit |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eribulin Injection [Halaven] CI brief — competitive landscape report
- Eribulin Injection [Halaven] updates RSS · CI watch RSS
- Institut fuer Frauengesundheit portfolio CI
Frequently asked questions about Eribulin Injection [Halaven]
What is Eribulin Injection [Halaven]?
Eribulin Injection [Halaven] is a Small molecule drug developed by Institut fuer Frauengesundheit.
Who makes Eribulin Injection [Halaven]?
Eribulin Injection [Halaven] is developed and marketed by Institut fuer Frauengesundheit (see full Institut fuer Frauengesundheit pipeline at /company/institut-fuer-frauengesundheit).
Is Eribulin Injection [Halaven] also known as anything else?
Eribulin Injection [Halaven] is also known as Eribulin.
What development phase is Eribulin Injection [Halaven] in?
Eribulin Injection [Halaven] is FDA-approved (marketed).
Related
- Manufacturer: Institut fuer Frauengesundheit — full pipeline
- Also known as: Eribulin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing